Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06596694 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)

StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Lead sponsor: Merck Sharp & Dohme LLC to Merck Sharp & Dohme LLC Enrollment closed, study ongoing · Eligibility criteria expanded, about 13 words · Secondary endpoints: details revised at 2 of 5 entries · 1 more Show 4 more changesShow less
    • Enrollment closed, study ongoing
    • Eligibility criteria expanded, about 13 words
    • Secondary endpoints: details revised at 2 of 5 entries
    • Study sites revised (62)
  2. Site details revised at 2 of 62 sitesv47
  3. Re-verified, no change to tracked fieldsv46
  4. Site details revised at 1 of 62 sitesv45
  5. Site details revised at 1 of 62 sitesv44
Show 42 earlier versionsHide 42 earlier versions
  1. Site details revised at 1 of 62 sitesv43
  2. Site details revised at 1 of 62 sitesv42
  3. Site details revised at 2 of 62 sitesv41
  4. Site details revised at 1 of 62 sitesv40
  5. Site details revised at 2 of 62 sitesv39
  6. Site contacts updated at 1 of 62 sitesv38
  7. Site contacts updated at 3 of 62 sitesv37
  8. Site contacts updated at 1 of 62 sitesv36
  9. Site contacts updated at 3 of 62 sitesv35
  10. Primary and study completion dates: Jul 24, 2028 to Dec 7, 2028v34
  11. Site contacts updated at 1 of 62 sitesv33
  12. Enrollment target: 130 to 180 Eligibility criteria expanded, about 13 words · Secondary endpoints: details revised at 5 of 5 entriesv32 Show 2 more changesShow less
    • Eligibility criteria expanded, about 13 words
    • Secondary endpoints: details revised at 5 of 5 entries

    See this version in full on ClinicalTrials.gov ↗

  13. Site details revised at 3 of 62 sitesv31
  14. Study sites: 61 to 62v30
  15. Site contacts updated at 1 of 61 sitesv29
  16. Site contacts updated at 3 of 61 sitesv28
  17. Study sites: 59 to 61v27
  18. Site details revised at 1 of 59 sitesv26
  19. Study sites: 58 to 59v25
  20. Study sites: 55 to 58v24
  21. Study sites: 54 to 55v23
  22. Study sites: 53 to 54v22
  23. Study sites: 52 to 53v21
  24. Re-verified, no change to tracked fieldsv20
  25. Site contacts updated at 5 of 52 sitesv19
  26. Study sites: 51 to 52v18
  27. Site contacts updated at 3 of 51 sitesv17
  28. Study sites: 48 to 51 Study title expanded, about 1 wordv16 Show 1 more changeShow less
    • Study title expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  29. Study sites: 46 to 48v15
  30. Study sites: 44 to 46v14
  31. Primary endpoints revised (4) Study sites: 39 to 44 · Eligibility criteria expanded, about 20 words · Secondary endpoints revised (5)v13 Show 3 more changesShow less
    • Study sites: 39 to 44
    • Eligibility criteria expanded, about 20 words
    • Secondary endpoints revised (5)

    See this version in full on ClinicalTrials.gov ↗

  32. Eligibility criteria revisedv12 See this version in full on ClinicalTrials.gov ↗
  33. Study sites: 36 to 39v11
  34. Study sites: 24 to 36v10
  35. Study sites: 22 to 24v9
  36. Study sites: 16 to 22v8
  37. Study sites: 12 to 16v7
  38. Study sites: 9 to 12v6
  39. Study sites: 8 to 9v5
  40. Study sites: 7 to 8v4
  41. Study sites: 2 to 7 Start date changed from estimate of Oct 30, 2024 to Nov 3, 2024v3 Show 1 more changeShow less
    • Start date changed from estimate of Oct 30, 2024 to Nov 3, 2024
  42. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 2 · Start date: Oct 16, 2024 to Oct 30, 2024v2 Show 2 more changesShow less
    • Study sites: 0 to 2
    • Start date: Oct 16, 2024 to Oct 30, 2024
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Merck (MSD)
407 trials monitored
See 29 trials at risk
Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are advanced (the cancer has spread to other parts of the body). The goals of this study are to learn: * About the safety and how well people tolerate of patritumab deruxtecan * How many people have the cancer respond (get smaller or go away) to treatment
Trial Details
NCT Number NCT06596694
Lead Sponsor Merck Sharp & Dohme LLC
Collaborators: Daiichi Sankyo
Conditions Gastrointestinal Cancer
Enrollment 180 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov